Literature DB >> 23241733

Colistin in critically ill patients.

M Boisson1, N Gregoire, W Couet, O Mimoz.   

Abstract

Colistin is a re-emerging old antibiotic that is used as a salvage treatment against multidrug-resistant Gram-negative infections. Because it is administrated as an inactive prodrug, colistin methanesulfonate (CMS) that undergoes rapid hydrolyze to colistin, pharmacokinetic studies using biological assays are unreliable. With the recent development of new assays using high performance liquid chromatography (HPLC) accurate pharmacokinetic of CMS and formed colistin is now available in various populations. This article aims to update previous reports on pharmacodynamics, pharmacokinetics, safety and clinical use of colistin, with a special focus on data useful to treat critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23241733

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  6 in total

1.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Mei-Ling Han; Nikolas J Onufrak; Ke Chen; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Antimicrobial dosing in critically ill patients with sepsis-induced acute kidney injury.

Authors:  Shakti Bedanta Mishra; Afzal Azim
Journal:  Indian J Crit Care Med       Date:  2015-05

4.  Survival or Safety: Balancing act with Colistin.

Authors:  Saiprasad Patil; Kapil Zirpe; Dipnarayan Mukherjee; Anoop Hajare; Krishnaprasad Korukonda; Amit Bhargava
Journal:  J Glob Infect Dis       Date:  2015 Jan-Mar

5.  Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. A randomised, double blind trial.

Authors:  Christian Schoergenhofer; Peter Matzneller; Marion Mußbacher; Johannes A Schmid; Petra Jilma-Stohlawetz; Markus Zeitlinger; Bernd Jilma
Journal:  Thromb Haemost       Date:  2017-08-10       Impact factor: 5.249

6.  Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections.

Authors:  Svetlana Sadyrbaeva-Dolgova; Ricardo García-Fumero; Manuela Exposito-Ruiz; Juan Pasquau-Liaño; Alberto Jiménez-Morales; Carmen Hidalgo-Tenorio
Journal:  Sci Rep       Date:  2022-09-10       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.